Loading...
Market
What will be the nature of the first major lawsuit related to biosimilar market entry by the end of 2025?
2
Resolution / Starting Odds
Pharmaceutical company vs FDA • 25%
Pharmaceutical company vs another pharmaceutical company • 25%
Consumer group vs FDA • 25%
Other • 25%
Court records or official announcements from involved parties
Story
FTC Supports FDA Proposal for Easier Biosimilar Market Entry
Aug 20, 2024, 06:31 PM
The Federal Trade Commission (FTC) has expressed support for a proposed guidance by the U.S. Food and Drug Administration (FDA) aimed at facilitating the market entry of biosimilar drugs. This proposal is designed to make it easier for drugmakers to demonstrate that biosimilar medicines are safe and effective substitutes for more expensive brand-name drugs. Biosimilars offer patients access to life-saving medications at more affordable prices, potentially impacting the pharmaceutical market significantly. The FTC's backing highlights the economic considerations and antitrust implications of biosimilar market entry, which are comparable to those of generic drugs. The proposal could streamline the approval process, enhancing competition and reducing healthcare costs.
View original story
Similar markets
Drug A • 25%
Drug B • 25%
Drug C • 25%
Other • 25%
Eli Lilly • 33%
Novo Nordisk • 33%
Sanofi • 33%
None • 1%
Patent infringement lawsuit • 25%
Settlement agreement • 25%
Licensing agreement • 25%
No major legal action • 25%
Nintendo and The Pokémon Company win • 25%
Pocketpair Inc. wins • 25%
Settlement reached • 25%
Case dismissed • 25%
Yes • 50%
No • 50%
Eli Lilly • 33%
Novo Nordisk • 33%
Sanofi • 33%
No lawsuit filed • 1%
Yes • 50%
No • 50%
Cassava Sciences wins the lawsuits • 25%
Cassava Sciences settles the lawsuits • 25%
Cassava Sciences loses the lawsuits • 25%
Lawsuits are dismissed • 25%
In Favor of Screening • 25%
Against Screening • 25%
Settlement Reached • 25%
Case Dismissed • 25%